Informations générales (source: ClinicalTrials.gov)
Evaluation of MassArray Platform Versus Illumina Miseq for the Detection of Driver Mutations in Hematological Malignancies (MAHM)
Observational
University Hospital, Strasbourg, France (Voir sur ClinicalTrials)
décembre 2018
décembre 2019
29 juin 2024
Detection of somatic mutations in hematological malignancies is now routinely assessed by
NGS sequencing. This powerful approach is nevertheless time consuming and its costs
represent limitation for its availability. An original approach is now available, using
mass spectrometry (MS). In this study the analytical performance of both methods will be
compared, using samples that were previously analyzed by NGS.
The goal of the study is to assess whether MS can represent or not a faster and cheaper
way to detect key point mutations in patients suffering from hematological malignancies
Etablissements
| Les établissements hors Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| Laboratoire d'Hématologie - 67098 - Strasbourg - France | Laurent MAUVIEUX, MD, PhD | Contact (sur clinicalTrials) | |||
Critères
Tous
Inclusion Criteria:
- adults >18 years old
- anonymized samples already studied with NGS in Strasbourg university hematology
center for somatic mutations
- non-opposition of the patient for testing the archive sample with the new method
- adults >18 years old
- anonymized samples already studied with NGS in Strasbourg university hematology
center for somatic mutations
- non-opposition of the patient for testing the archive sample with the new method
- opposition for testing the archive sample with the new method
- insufficient archival material
- patient under protection